Expression of the novel T cell activation molecule hpH4 in HIV-infected patients: Correlation with disease status

AIDS Research and Human Retroviruses

Volumn 16, Issue 6, 2000, Pages 549-557

  Lucia, Mothanje B ^a   Buonfiglio, Donatella ^b   Bottarel, Flavia ^b   Bensi, Thea ^b   Rutella, Sergio ^a   Rumi, Carlo ^a   Ortona, Luigi ^a   Janeway Jr , Charles A ^c   Cauda, Roberto ^a   Dianzani, Umberto ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN HPH4; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADP-RIBOSYL CYCLASE; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NAD+ NUCLEOSIDASE; RECEPTORS, INTERLEUKIN-2; TIME FACTORS;

EID: 0034630297     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308963     Document Type: Article

References (33)

1. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature (London) 1996;12:529-534.
2. Melbye MR, Biggar J, Ebbesen P, Neuland C, Goedert JJ, Lorenzer IB, Skinhoj PR, Gallo RC, and Blattner WA: Long-term seropositivity for human T lymphotropic virus type III in homosexual men without acquired immunodeficiency syndrome: Development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med 1986;104:496-500.
3. Polk BF, Fox R, Brookmeyer R, Kanchanaraska S, Kaslow R, Visscher B, Rinaldo C, and Phair J: Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987;316:61-66.
4. Giorgi JV, Fahey JL, Smith DC, Hultin LE, Cheng HL, Mitsuyasu RT, and Detels R: Early effects of HIV on CD4 lymphocytes in vivo. J Immunol 1987;138:3725-3730.
5. Roos MT, Lange JM, de Goede RE, Coutinho RA, Schellekens PT, Miedema F, and Tersmette M: Virus phenotype and immune response in primary human immunodeficiency virus type 1 (HIV-1) infection. J Infect Dis 1992;165:427-432.
6. + T cells in HIV-1-infected patients. AIDS 1996;10:827-834.
7. + T cells is a marker of poor prognosis in HIV infection: Results of 6 years of follow-up. Cytometry 1996;26:1-7.
8. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83-92.
9. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, and Metha K: Human CD38: A glycoprotein in search of a function. Immunol Today 1994;15:95-97.
10. Redoglia V, Dianzani U, Rojo JM, Portoles P, Bragardo M, Wolff H, Buonfiglio D, Bonissoni S, and Janeway CA Jr: Characterization of H4: A murine T lymphocyte activation molecule functionally associated with the CD3/TCR. Eur J Immunol 1996;26:2781-2789.
11. Buonfiglio D, Bragardo M, Bonissoni S, Redoglia V, Cauda R, Zupo S, Burgio VL, Wolff H, Franssila K, Gaidano G, Carbone A, Janeway CA Jr, and Dianzani U: Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells, and subsets of T-cell lymphomas. Eur J Immunol 1999;29:2863-2874.
12. Dianzani U, Bragardo M, Buonfiglio D, Redoglia V, Funaro A, Portoles P, Rojo JM, Malavasi F, and Pileri A: Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120. Eur J Immunol 1995;25:1306-1311.
13. Dianzani U, Bragardo M, DiFranco D, Alliaudi C, Scagni P, Buonfiglio D, Redoglia V, Bonissoni S, Correra A, Dianzani I, and Ramenghi U: Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lympho-proliferation. Blood 1997;89:2871-2879.
14. + T cells. AIDS Res Hum Retroviruses 1999;15:1255-1263.
15. McGuiness D, Bennett S, and Riley E: Statistical analysis of highly skewed immune response data. J Immunol Methods 1997;201:99-114.
16. Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, and Gaudino G: Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 1998;17:741-749.
17. Feito MJ, Bragardo M, Buonfiglio D, Bonissoni S, Bottarel F, Malavasi F, and Dianzani U: gp120s derived from four HIV-1 strains induce different patterns of CD4 association with lymphocyte surface molecules. Int Immunol 1997;9:1141-1147.
18. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, and Finkel TH: Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992;176:1099-1106.
19. Capon DJ and Ward RHR: The CD4-gp120 interaction and AIDS pathogenesis. Annu Rev Immunol 1991;9:649-678.
20. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, and Krammer PH: Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (London) 1995;375:497-500.
21. Nagata S and Golstein P: The Fas death factor. Science 1995;267:1449.
22. Rautonen J, Rautonen N, Martin NL, Philip R, and Wara DW: Serum interleukin-6 concentrations are elevated and associated with elevated tumor necrosis factor and immunoglobulin G and A concentrations in children with HIV infection. AIDS 1991;5:1319-1325.
23. Shearer GM and Clerici M: Protective immunity against HIV infection: Has nature done the experiment for us? Immunol Today 1996;17:21-24.
24. Hofmann B, Nishanian P, Fahey JL, Esmail I, Jackson AL, Detels R, and Cumberland WG: Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: Distinctive parameters of HIV-induced change. Clin Immunol Immunopathol 1991;61:212-224.
25. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993;69:106-116.
26. + cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993;150:3070-3079.
27. Amadori A, Zamarchi R, and Chieco-Bianchi L: CD4:CD8 ratio and HIV infection: "The tap-and-drain" hypothesis. Immunol Today 1996;17:414-417.
28. Li CJ, Friedman DJ, Wang C, Metelev V, and Pardee AB: Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995;268:429-431.
29. Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, Chirmule N, McCloskey T, Pahwa S, and Verdin E: Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997;275:1481-1485.
30. + T lymphocytes. J Immunol 1996;157:2216-2224.
31. Westby M, Manca F, and Dalgleish AG: The role of immune response in determining the outcome of HIV infection. Immunol Today 1996;17:120-126.
32. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry co-factor: Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996;272:872-877.
33. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, and Sodroski J: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.